Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04342910 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

StatusRecruiting
PhasePhase 3
Started2020-09-21
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 20, 2026 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-01-15
Study Status v3
Primary completion date2022-04-01→2026-04-01
Completion date2022-09-01→2026-09-01
2021-02-20
Study Status, Eligibility, Contacts/Locations v2
Re-verified, no change to tracked fields
2020-11-17
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2020-06-01→confirmed 2020-09-21
2020-04-10
Original filing
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.
Trial Details
NCT Number NCT04342910
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Gastric Cancer
Enrollment 550 participants
Start Date 2020-09-21
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-20